Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29658430

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2018 May 10
First author
Eggermont AMM

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Cancer Discov. 2018 Jun;8(6):666-667. doi: 10.1158/2159-8290.CD-NB2018-047.
    note
    Source null
    related pmid
    29657137
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2018 Sep;15(9):535-536. doi: 10.1038/s41571-018-0048-5.
    note
    Source null
    related pmid
    29849093
    relationship
    Comment in
  3. citation
    Immunity. 2018 Jun 19;48(6):1077-1080. doi: 10.1016/j.immuni.2018.06.003.
    note
    Source null
    related pmid
    29924973
    relationship
    Comment in
  4. citation
    N Engl J Med. 2018 Aug 09;379(6):593. doi: 10.1056/NEJMc1807505.
    note
    Source null
    related pmid
    30091350
    relationship
    Comment in

Authors and identifiers

  1. name
    Eggermont AMM
    type
    Author
  2. name
    Blank CU
    type
    Author
  3. name
    Mandala M
    type
    Author
  4. name
    Long GV
    type
    Author
  5. name
    Atkinson V
    type
    Author
  6. name
    Dalle S
    type
    Author
  7. name
    Haydon A
    type
    Author
  8. name
    Lichinitser M
    type
    Author
  9. name
    Khattak A
    type
    Author
  10. name
    Carlino MS
    type
    Author
  11. name
    Sandhu S
    type
    Author
  12. name
    Larkin J
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Eggermont AMM
    type
    Author
  2. name
    Blank CU
    type
    Author
  3. name
    Mandala M
    type
    Author
  4. name
    Long GV
    type
    Author
  5. name
    Atkinson V
    type
    Author
  6. name
    Dalle S
    type
    Author
  7. name
    Haydon A
    type
    Author
  8. name
    Lichinitser M
    type
    Author
  9. name
    Khattak A
    type
    Author
  10. name
    Carlino MS
    type
    Author
  11. name
    Sandhu S
    type
    Author
  12. name
    Larkin J
    type
    Author
bibliography ids
  1. nci-bib-86d50d0db64104b7f3148dd5
book metadata
content sha256
534bff6458393902aa0fff5c5a62020dd6eda9091b4df91972a54445a7f54f8b
document type
citation
dois
  1. 10.1056/NEJMoa1802357
electronic publication date
display
2018 Apr 15
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:29658430
immutable id
pubmed:29658430@534bff6458393902aa0fff5c5a62020dd6eda9091b4df91972a54445a7f54f8b
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
19
name
The New England journal of medicine
nlm unique id
0255562
pages
1789-1801
volume
378
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Cancer Discov. 2018 Jun;8(6):666-667. doi: 10.1158/2159-8290.CD-NB2018-047.
    note
    Source null
    related pmid
    29657137
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2018 Sep;15(9):535-536. doi: 10.1038/s41571-018-0048-5.
    note
    Source null
    related pmid
    29849093
    relationship
    Comment in
  3. citation
    Immunity. 2018 Jun 19;48(6):1077-1080. doi: 10.1016/j.immuni.2018.06.003.
    note
    Source null
    related pmid
    29924973
    relationship
    Comment in
  4. citation
    N Engl J Med. 2018 Aug 09;379(6):593. doi: 10.1056/NEJMc1807505.
    note
    Source null
    related pmid
    30091350
    relationship
    Comment in
outcomes validated
false
pmid
29658430
provenance
batch id
c4c0356d060413f719c2
provider
NCBI PubMed ESummary
record sha256
ebcb3a1e2b894f035f71803e29826d11b0bda6c234479d65eb54ec35173f36fa
response sha256
adeb6beaad718f060a94981fd9e96a2eaddc4f781839549cb3e53cba822117c0
retrieved at
2026-09-09T23:47:33.674758+00:00
publication date
display
2018 May 10
precision
day
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/29658430/
title
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Preserved source evidence · Not medical advice